

House Bill 830

By: Representatives Harden of the 148th, Stephens of the 164th, Parrish of the 158th, and Taylor of the 173rd

A BILL TO BE ENTITLED
AN ACT

1 To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to
2 controlled substances, so as to change certain provisions relating to Schedules I and II
3 controlled substances; to change certain provisions relating to the definition of dangerous
4 drug; to provide for related matters; to provide an effective date; to repeal conflicting laws;
5 and for other purposes.

6 BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:

7 **SECTION 1.**

8 Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled
9 substances, is amended in Code Section 16-13-25, relating to Schedule I controlled
10 substances, by adding a new subparagraph to paragraph (3) to read as follows:

11 "(GGGG) Fluorophenmetrazine;"

12 **SECTION 2.**

13 Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled
14 substances, by revising division (ii) of subparagraph (L) of paragraph (12) as follows:

15 "(ii) By substitution at the 3-position with an acyclic alkyl substitution or alkoxy
16 substitution; or"

17 **SECTION 3.**

18 Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled
19 substances, by revising division (ii) of subparagraph (E) of paragraph (13) as follows:

20 "(ii) Acetamide group, which itself can be further substituted with:

21 (I) ~~Cyclic~~ cyclic alkyl group;

22 (II) Tetrahydrofuran group;"

23 **SECTION 4.**

24 Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled
 25 substances, by revising the introductory text of paragraph (15) as follows:

26 "(15) The 1-cyclohexyl-4-(1,2-~~diphenylethy~~ diphenylethyl)-piperazine (MT-45)
 27 structural class, including any of the following derivatives, their salts, isomers, or salts
 28 of isomers, unless specifically utilized as part of the manufacturing process by a
 29 commercial industry of a substance or material not intended for human ingestion or
 30 consumption, as a prescription administered under medical supervision, or for research
 31 at a recognized institution, whenever the existence of these salts, isomers, or salts of
 32 isomers is possible within the specific chemical designation or unless specifically
 33 excepted or listed in this or another schedule, structurally derived from
 34 1-cyclohexyl-4-(1,2-~~diphenylethy~~ diphenylethyl)-piperazine (MT-45), and whether or not
 35 further modified in any of the following ways:"

36 **SECTION 5.**

37 Said chapter is further amended in Code Section 16-13-26, relating to Schedule II controlled
 38 substances, by substituting the "." at the end of paragraph (4) with a ";" and by adding a new
 39 paragraph to read as follows:

40 "(5) Dronabinol in oral solution labeled in compliance with U.S. Food and Drug
 41 Administration requirements."

42 **SECTION 6.**

43 Said chapter is further amended in Code Section 16-13-71, relating to the definition of
 44 "dangerous drug," by adding new paragraphs to subsection (b) to read as follows:

45 "(.031) Abaloparatide;"

46 "(.041) Abemaciclib;"

47 "(.044) Acalabrutinib;"

48 "(51.5) Angiotensin II;"

49 "(69.11) Avelumab;"

50 "(83.11) Benralizumab;"

51 "(84.1) Benznidazole;"

52 "(97.11) Betrixaban;"

53 "(107.4) Brigatinib;"

54 "(107.6) Brodalumab;"

55 "(159.9) Cerliponase alfa;"

56 "(213.4) Copanlisib;"

57 "(244.3) Deflazacort;"

- 58 "(244.41) Delafloxacin;"
59 "(256.6) Deutetrabenazine;"
60 "(325.46) Dupilumab;"
61 "(325.47) Durvalumab;"
62 "(330.4) Edaravone;"
63 "(331.0701) Emicizumab;"
64 "(331.7) Enasidenib;"
65 "(346.7) Ertugliflozin"
66 "(355.7) Etelcalcetide;"
67 "(415.04) Glecaprevir;"
68 "(432.91) Guselkumab;"
69 "(474.1) Inotuzumab ozogamicin;"
70 "(512.8) Latanoprostene bunod;"
71 "(513.78) Letemovir;"
72 "(534.3) Macimorelin;"
73 "(617.2) Midostaurin;"
74 "(632.1) Naldemedine;"
75 "(640.11) Neratinib maleate;"
76 "(640.25) Netarsudil"
77 "(644.61) Niraparib;"
78 "(661.2) Ocrelizumab;"
79 "(680.3) Ozenoxacin;"
80 "(731.01) Pibrentasvir"
81 "(742.1) Plecanatide;"
82 "(838.6) Ribociclib;"
83 "(849.8) Safinamide;"
84 "(851.2) Sarilumab;"
85 "(852.06) Secnidazole;"
86 "(853.9) Semaglutide;"
87 "(931.61) Telotristat ethyl;"
88 "(1021.61) Vaborbactam;"
89 "(1021.71) Valbenazine;"
90 "(1029.6) Vestronidase alfa-vjbk;"
91 "(1037.9) Voxilaprevir;"

92 **SECTION 7.**

93 Said chapter is further amended in Code Section 16-13-71, relating to the definition of
94 "dangerous drug," by revising paragraph (516.75) of subsection (b) as follows:

95 "(516.75) Levocetirizine — See exceptions;"

96 **SECTION 8.**

97 Said chapter is further amended in Code Section 16-13-71, relating to the definition of
98 "dangerous drug," by adding a paragraph in subsection (c) to read as follows:

99 "(12.91) Levocetirizine — when a single dose unit is either 2.5 mg. per 5 ml. or less or
100 5 mg. or less;"

101 **SECTION 9.**

102 Said chapter is further amended in Code Section 16-13-71, relating to the definition of
103 "dangerous drug," by amending paragraph (13) in subsection (c) to read as follows:

104 "(13) Lidocaine topical, ~~ointment, 25 mg./gm.~~ 40 mg./gm. (4%) or less;"

105 **SECTION 10.**

106 This Act shall become effective upon its approval by the Governor or upon its becoming law
107 without such approval.

108 **SECTION 11.**

109 All laws and parts of laws in conflict with this Act are repealed.